Cancer Research AACR Legacy  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 52, 6501-6506, December 1, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Esaki, T.
Right arrow Articles by Niho, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Esaki, T.
Right arrow Articles by Niho, Y.

Inhibition by 5-Fluorouracil of cis-Diamminedichloroplatinum(II)-induced DNA Interstrand Cross-Link Removal in a HST-1 Human Squamous Carcinoma Cell Line

Taito Esaki, Shuji Nakano1, Takashi Tatsumoto, Mika Kuroki-Migita, Kenji Mitsugi, Minoru Nakamura and Yoshiyuki Niho

First Department of Internal Medicine, Faculty of Medicine, Kyushu University, 3-1-1 Maidashi, Fukuoka, Fukuoka 812, Japan

1 To whom requests for reprints should be addressed.

To elucidate the mechanism of the synergistic cytotoxicity of 5-fluorouracil (5-FU) and cis-diamminedichloroplatinum(II) (CDDP), we studied the interaction of these agents using a human squamous carcinoma cell line (HST-1). Exposure to 5-FU for 24 h and to CDDP for 1 h produced a 50% inhibitory concentration of 1.0 µg/ml (7.7 µm) and 2.5 µg/ml (8.3 µm), respectively. The cytotoxic action of CDDP was augmented, and a greater than additive effect was observed when the cells were exposed to 5-FU (1.0 µg/ml; 7.7 µm) for 24 h before the CDDP treatment. This synergistic activity was maximal when the interval between 5-FU and CDDP exceeded 24 h. In contrast, the cytotoxicity of CDDP was attenuated when it preceded the exposure to 5-FU. Thymidine did not alter the 5-FU-CDDP interaction. Evaluation of the kinetics of the removal of DNA interstrand cross-links, measured by alkaline elution, showed a significant reduction of this removal in the cells exposed to 5-FU followed by CDDP with a drug-free interval of 48 h, as compared with cells exposed to CDDP alone, or to 5-FU immediately followed by CDDP, although no differences were found in the formation of DNA interstrand cross-links by CDDP among these cells. No significant differences in the accumulation of intracellular platinum were detected by atomic absorption spectrophotometry. These findings suggest that 5-FU modulates the repair of platinum-DNA adducts, thereby potentiating the antitumor activity of CDDP.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 6/16/92. Accepted 9/24/92.




This article has been cited by other articles:


Home page
Anticancer ResHome page
E. BABA, H. FUJISHIMA, H. KUSABA, T. ESAKI, H. ARIYAMA, K. KATO, R. TANAKA, K. MITSUGI, Y. SHIBATA, M. HARADA, et al.
Phase I Study of the Sequential Administration of S-1 and Cisplatin for Metastatic Gastric Cancer
Anticancer Res, May 1, 2009; 29(5): 1727 - 1732.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
D. Galetta, A. Cesario, S. Margaritora, V. Porziella, G. Macis, R. M. D'Angelillo, L. Trodella, S. Sterzi, and P. Granone
Enduring challenge in the treatment of nonsmall cell lung cancer with clinical stage IIIB: results of a trimodality approach
Ann. Thorac. Surg., December 1, 2003; 76(6): 1802 - 1809.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Nishiyama, W. Yamamoto, J.-S. Park, R. Okamoto, H. Hanaoka, H. Takano, N. Saito, M. Matsukawa, T. Shirasaka, and M. Kurihara
Low-Dose Cisplatin and 5-Fluorouracil in Combination CanRepress Increased Gene Expression of Cellular Resistance Determinants to Themselves
Clin. Cancer Res., September 1, 1999; 5(9): 2620 - 2628.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. Zeghari-Squalli, E. Raymond, E. Cvitkovic, and F. Goldwasser
Cellular Pharmacology of the Combination of the DNA Topoisomerase I Inhibitor SN-38 and the Diaminocyclohexane Platinum Derivative Oxaliplatin
Clin. Cancer Res., May 1, 1999; 5(5): 1189 - 1196.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.